Migraine.site - information about the fixed dose combination of naproxen and sumatriptan MIGSUNTM and the treatment of acute migraine

This section is aimed at healthcare professionals.

About product

Migsun brand logo

Sumatriptan/naproxen sodium tablets

Suvexx brand logo Nomanesit logo Sumanet brand logo

Prescribing information available here

Adverse event reporting information can be found at the bottom of this page

Welcome to Migraine.site

Introducing our website, dedicated to providing a wealth of valuable content on the cutting-edge treatment of migraines. Whether you're a general practitioner seeking to enhance your understanding or an expert delving deeper into novel therapies, our platform offers comprehensive insights, research updates, and practical guidance.

From emerging pharmacological interventions to holistic approaches, we cover the spectrum of migraine management. Stay abreast of the latest advancements, connect with fellow professionals, and empower your practice with evidence-based strategies. Welcome to a hub designed to elevate your expertise and improve patient care in the realm of migraine treatment.

Webinar

Webinar on acute migraine treatment

Hear insights on migraine from the European top experts, chaired by prof. Peter Goadsby:

  • Migraine - Pathophysiology / Epidemiology / Burden / Stigma
  • Acute migraine treatment - Treatment guidelines
  • Special condition migraine
  • Pharmacokinetics of sumatriptan-naproxen combination
  • Sumatriptan-naproxen combination clinical data
Watch webinar here
Product information

MigsunTM as a treatment

MIGSUNTM is a combination of two commonly used acute migraine medications in a single tablet: sumatriptan 85 mg and naproxen sodium 500 mg. Read more

The product will be available in Europe with the following names: SUVEXXTM, FRIMIG DUOTM, MIGSUNTM, NOMANESITTM, NOMIGRIN®, and SUMANETTM. 

As at now the market authorization has been granted for 

  • SUMANETTM in Austria
  • FRIMIG® DUO in Poland
  • MIGSUNTM  in Estonia, Latvia, Lithuania and Ireland
  • NOMIGRIN® in Finland
Read about product
Product information

Summary of product characteristics (SmPC)

Find prescribing information here

Publications

Publications

Get short summaries of the most important publications

 

About treatment of acute migraine with NSAIDs and triptans, the case of combination of sumatriptan-naproxen 85mg/500mg

Burden of migraine. Treatment of migraine: what's new?

We are Orion Pharma

International medical excellence

Orion Pharma is a Finnish pharmaceutical company – a builder of well-being with global operations. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. 

> Get to know us better

Patients' well-being in the core

We collaborate closely with healthcare professionals and leading global research institutions and pharmaceutical companies. Together we take care of patients’ well-being.

> Read about research and development

Our values & sustainability

We build in all collaboration on mutual trust, appreciation, and diversity. We fight diseases by innovative treatments to improve quality of lives. We know the effects of and requirements for our operations and take responsibility for the entire life cycle of the product.  

> Sustainability at Orion

Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com